TXG
Income statement / Annual
Last year (2023), 10x Genomics, Inc.'s total revenue was $618.73 M,
an increase of 19.81% from the previous year.
In 2023, 10x Genomics, Inc.'s net income was -$255.10 M.
See 10x Genomics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$618.73 M
|
$516.41 M
|
$490.49 M
|
$298.85 M
|
$245.89 M
|
$146.31 M
|
$71.09 M
|
| Cost of Revenue |
$209.41 M |
$120.39 M |
$74.09 M |
$58.47 M |
$61.03 M |
$28.66 M |
$10.56 M |
| Gross Profit |
$409.31 M |
$396.02 M |
$416.40 M |
$240.38 M |
$184.86 M |
$117.65 M |
$60.53 M |
| Gross Profit Ratio |
0.66 |
0.77 |
0.85 |
0.8 |
0.75 |
0.8 |
0.85 |
| Research and Development
Expenses |
$270.33 M
|
$265.67 M
|
$211.75 M
|
$123.38 M
|
$83.10 M
|
$47.54 M
|
$32.16 M
|
| General & Administrative
Expenses |
$340.03 M
|
$294.60 M
|
$252.86 M
|
$200.43 M
|
$129.33 M
|
$87.24 M
|
$46.54 M
|
| Selling & Marketing
Expenses |
$3.30 M
|
$3.70 M
|
$4.70 M
|
$1.90 M
|
$1.50 M
|
$700,000.00
|
$200,000.00
|
| Selling, General &
Administrative Expenses |
$343.33 M
|
$298.30 M
|
$257.56 M
|
$202.33 M
|
$130.83 M
|
$87.94 M
|
$46.74 M
|
| Other Expenses |
$0.00 |
-$198,000.00 |
-$802,000.00 |
$1.34 M |
-$186,000.00 |
-$249,000.00 |
$137,000.00 |
| Operating Expenses |
$674.95 M |
$563.97 M |
$469.31 M |
$325.70 M |
$213.93 M |
$135.47 M |
$78.90 M |
| Cost And Expenses |
$884.36 M |
$684.35 M |
$543.40 M |
$384.17 M |
$274.96 M |
$164.13 M |
$89.46 M |
| Interest Income |
$16.91 M |
$6.65 M |
$206,000.00 |
$1.53 M |
$2.81 M |
$1.02 M |
$308,000.00 |
| Interest Expense |
$33,000.00 |
$476,000.00 |
$866,000.00 |
$1.68 M |
$3.08 M |
$2.41 M |
$811,000.00 |
| Depreciation &
Amortization |
$43.62 M
|
$33.01 M
|
$28.25 M
|
$19.02 M
|
$7.07 M
|
$3.91 M
|
$4.31 M
|
| EBITDA |
-$205.11 M
|
-$128.49 M
|
-$24.60 M
|
-$513.77 M
|
-$20.89 M
|
-$106.08 M
|
-$13.63 M
|
| EBITDA Ratio |
-0.33 |
-0.31 |
-0.11 |
-0.28 |
-0.11 |
-0.09 |
-0.19 |
| Operating Income Ratio
|
-0.43
|
-0.33
|
-0.11
|
-0.29
|
-0.12
|
-0.76
|
-0.26
|
| Total Other
Income/Expenses Net |
$16.57 M
|
$5.97 M
|
-$802,000.00
|
-$449.15 M
|
-$1.96 M
|
-$1.63 M
|
-$366,000.00
|
| Income Before Tax |
-$248.76 M |
-$161.97 M |
-$53.72 M |
-$534.48 M |
-$31.03 M |
-$112.40 M |
-$18.74 M |
| Income Before Tax Ratio
|
-0.4
|
-0.31
|
-0.11
|
-1.79
|
-0.13
|
-0.77
|
-0.26
|
| Income Tax Expense |
$6.34 M |
$4.03 M |
$4.51 M |
$8.26 M |
$218,000.00 |
$87,000.00 |
$21,000.00 |
| Net Income |
-$255.10 M |
-$166.00 M |
-$58.22 M |
-$542.73 M |
-$31.25 M |
-$112.49 M |
-$18.76 M |
| Net Income Ratio |
-0.41 |
-0.32 |
-0.12 |
-1.82 |
-0.13 |
-0.77 |
-0.26 |
| EPS |
-2.18 |
-1.46 |
-0.53 |
-5.37 |
-0.8 |
-8.4 |
-1.62 |
| EPS Diluted |
-2.18 |
-1.46 |
-0.53 |
-5.37 |
-0.8 |
-8.4 |
-1.62 |
| Weighted Average Shares
Out |
$117.17 M
|
$113.86 M
|
$110.35 M
|
$101.15 M
|
$39.06 M
|
$13.39 M
|
$11.59 M
|
| Weighted Average Shares
Out Diluted |
$117.17 M
|
$113.86 M
|
$110.35 M
|
$101.15 M
|
$39.09 M
|
$13.39 M
|
$11.59 M
|
| Link |
|
|
|
|
|
|
|
